Browse Category

Biotechnology 9 December 2025 - 16 December 2025

Iovance shares surge 43% as Amtagvi revenue highlights manufacturing turning point
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead

Dec. 16, 2025 — uniQure N.V. is back in the spotlight Tuesday after a notable extended-hours rebound. The gene therapy developer’s shares were highlighted among top pre-market gainers, rising about 15% to roughly $23.50 in early trading, following a strong after-hours move the prior session. StockAnalysis+1
16 December 2025
··
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome, Inc. is in the spotlight on December 16, 2025, after the company reported positive topline Phase 3 results for its lead desmoid tumor program and then moved to raise significant new capital—two catalysts that can push a biotech stock in opposite directions at the same time. On the one hand: a clear late-stage efficacy win that supports an FDA filing. On the other: a proposed $400 million common stock offering that introduces near-term dilution risk. Reuters+2Immunome Investors+2
16 December 2025
··
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited shares closed Friday at A$183.93, ending a volatile week only slightly lower overall after a sharp rebound into the weekend. Investors are weighing two very different storylines at once: encouraging long-term clinical data for CSL’s hemophilia B gene therapy HEMGENIX, and fresh scrutiny on Australia’s onshore vaccine manufacturing deals tied to CSL Seqirus — all while CSL continues to steadily mop up stock through its A$750 million on-market buyback. Global Newsroom | CSL+4Yahoo Finance+4Intelligent Investor+4
14 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals Incorporated finished Friday at $452.04, extending a late-week rebound after a choppy start to the week. The stock’s intraday range on Friday stretched from $442.94 to $455.99 on volume of about 1.62 million shares, as biotech investors weighed fresh pipeline headlines, Wall Street price-target moves, and a shifting macro backdrop following the Federal Reserve’s latest rate decision. MarketWatch+1
13 December 2025
··
Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Corporation stock is back in focus on December 12, 2025, as investors digest a sweeping restructuring tied to the company’s commercial push for RYTELO and its longer-term clinical ambitions. The headlines have been loud—one-third of the workforce is set to be cut, analysts are re-checking their models, and the market is weighing a familiar biotech question: is this the start of a leaner turnaround, or a sign that growth has stalled? Geron Corporation+2BioPharma Dive+2
12 December 2025
··
Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025)

Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025)

NEW YORK — December 12, 2025 — Applied Therapeutics, Inc. is in the spotlight after announcing a definitive agreement to be acquired by Cycle Group Holdings Limited, a rare-disease-focused company that operates as Cycle Pharmaceuticals. The headline terms include a small upfront cash payment and a potentially meaningful contingent value right tied to future FDA approvals and sales milestones—setting up a high-volatility, event-driven setup for APLT stock as the market digests what’s “real” value versus what’s optionality. GlobeNewswire
12 December 2025
···
10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off

10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off

10x Genomics, Inc. — a leading player in single-cell and spatial biology — is back in the spotlight after a sharp share-price drop on 11 December 2025. A high-profile analyst downgrade from Citigroup hit the stock the same morning, even as the company pushes forward with ambitious AI collaborations and cancer atlas projects that could shape its long-term growth story. MarketScreener+2StockStory+2
11 December 2025
····
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease.Immunovant, Inc.+1
11 December 2025
····
Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Arcellx, Inc. has jumped back onto Wall Street’s radar after releasing highly positive Phase 2 data for its multiple myeloma cell therapy anitocabtagene autoleucel at the American Society of Hematology 2025 meeting. The new data have driven a sharp move in the stock, a flurry of analyst updates, and renewed debate about valuation ahead of a planned 2026 commercial launch.
9 December 2025
··
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering and a wave of fresh analyst price‑target hikes.GlobeNewswire+3Investing.com+3Investing.com+3
9 December 2025
····
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after the company unveiled strong mid‑stage data for its once‑daily oral GLP‑1 obesity pill, aleniglipron. GlobeNewswire+2Investors+2
9 December 2025
··
iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

As of December 9, 2025, iBio, Inc. has turned into one of the louder tickers in the obesity‑drug corner of biotech. After closing Monday, December 8 at $1.67, up 39% on the day, IBIO is trading higher again in pre‑market action on Tuesday, with quotes between $1.76 and $1.81, pushing its market value to roughly $37–38 million.Benzinga
9 December 2025
·
1 … 11 12 13 14 15 … 21
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Constellation Energy

NASDAQ: CEG 95 / 100
#2 BUY

AerCap

NYSE: AER 93 / 100
#3 BUY

Walt Disney

NYSE: DIS 92 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 90 / 100
#5 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.